HRP20140787T1 - MAKROCIKLIÄŚKI DERIVATI UREE I SULFAMIDA KAO INHIBITORI TAFIa - Google Patents

MAKROCIKLIÄŚKI DERIVATI UREE I SULFAMIDA KAO INHIBITORI TAFIa Download PDF

Info

Publication number
HRP20140787T1
HRP20140787T1 HRP20140787AT HRP20140787T HRP20140787T1 HR P20140787 T1 HRP20140787 T1 HR P20140787T1 HR P20140787A T HRP20140787A T HR P20140787AT HR P20140787 T HRP20140787 T HR P20140787T HR P20140787 T1 HRP20140787 T1 HR P20140787T1
Authority
HR
Croatia
Prior art keywords
alkylene
formula
compound
alkyl
ureido
Prior art date
Application number
HRP20140787AT
Other languages
English (en)
Croatian (hr)
Inventor
Christopher Kallus
Mark Broenstrup
Andreas Evers
Anja Globisch
Herman Schreuder
Michael Wagner
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of HRP20140787T1 publication Critical patent/HRP20140787T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/01—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HRP20140787AT 2008-06-06 2009-05-22 MAKROCIKLIÄŚKI DERIVATI UREE I SULFAMIDA KAO INHIBITORI TAFIa HRP20140787T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290520 2008-06-06
PCT/EP2009/003650 WO2009146802A1 (de) 2008-06-06 2009-05-22 Makrocyclische harnstoff- und sulfamidderivate als inhibitoren von tafia

Publications (1)

Publication Number Publication Date
HRP20140787T1 true HRP20140787T1 (hr) 2014-11-21

Family

ID=39800716

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140787AT HRP20140787T1 (hr) 2008-06-06 2009-05-22 MAKROCIKLIÄŚKI DERIVATI UREE I SULFAMIDA KAO INHIBITORI TAFIa

Country Status (34)

Country Link
US (5) US8580777B2 (enExample)
EP (1) EP2300462B1 (enExample)
JP (1) JP5531011B2 (enExample)
KR (1) KR101673886B1 (enExample)
CN (1) CN102056922B (enExample)
AR (1) AR072007A1 (enExample)
AU (1) AU2009254257B2 (enExample)
BR (1) BRPI0913349A2 (enExample)
CA (1) CA2726554C (enExample)
CL (1) CL2009001358A1 (enExample)
CO (1) CO6321271A2 (enExample)
CR (1) CR11807A (enExample)
CY (1) CY1115604T1 (enExample)
DK (1) DK2300462T3 (enExample)
DO (1) DOP2010000363A (enExample)
EC (1) ECSP10010655A (enExample)
ES (1) ES2494390T3 (enExample)
HN (1) HN2010002558A (enExample)
HR (1) HRP20140787T1 (enExample)
IL (1) IL209772A (enExample)
MA (1) MA32322B1 (enExample)
MX (1) MX2010012793A (enExample)
NI (1) NI201000203A (enExample)
NZ (1) NZ589671A (enExample)
PL (1) PL2300462T3 (enExample)
PT (1) PT2300462E (enExample)
RU (1) RU2502736C2 (enExample)
SI (1) SI2300462T1 (enExample)
SV (1) SV2010003747A (enExample)
TW (1) TWI455928B (enExample)
UA (1) UA104002C2 (enExample)
UY (1) UY31868A (enExample)
WO (1) WO2009146802A1 (enExample)
ZA (1) ZA201007719B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101673886B1 (ko) 2008-06-06 2016-11-08 사노피 ＴＡＦＩａ의 억제제로서의 마크로사이클릭 우레아 및 술파미드 유도체
AR072278A1 (es) 2008-06-23 2010-08-18 Astrazeneca Ab Compuestos inhibidores de trombina
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
WO2013132376A1 (en) * 2012-03-06 2013-09-12 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
JP6461113B2 (ja) * 2013-06-10 2019-01-30 サノフイＳａｎｏｆｉ ＴＡＦＩａの阻害剤としての大環状尿素誘導体、それらの製造および医薬としての使用
UY35809A (es) * 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
CN103755852B (zh) * 2013-12-18 2015-12-09 湖北大学 线型聚苯乙烯支载(4s)-(4’-氧苄基)-2-正丁基环磺酰胺及其制备方法和用途
CN106631832A (zh) * 2016-10-08 2017-05-10 帕潘纳(北京)科技有限公司 一种氨基醚类化合物的制备方法
US10411291B2 (en) * 2017-03-22 2019-09-10 Nanotek Instruments, Inc. Multivalent metal ion battery having a cathode layer of protected graphitic carbon and manufacturing method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU667995B2 (en) 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
US5888971A (en) * 1996-02-20 1999-03-30 Ortho Pharmaceutical Corporation, Inc. Macrocyclic peptides useful in the treatment of thrombin related disorders
DE69824433D1 (en) 1997-08-28 2004-07-15 Biovitrum Ab Proteintyrosinphosphatase inhibitoren
US6124278A (en) * 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
US6482921B1 (en) 1999-01-28 2002-11-19 Essential Therapeutics, Inc. Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use
DE60042585D1 (de) * 2000-02-29 2009-09-03 Univ Firenze 3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla
PT2104497E (pt) 2006-12-06 2015-06-09 Sanofi Sa Derivados de ureia e sulfamida enquanto inibidores de tafia
KR101673886B1 (ko) 2008-06-06 2016-11-08 사노피 ＴＡＦＩａ의 억제제로서의 마크로사이클릭 우레아 및 술파미드 유도체

Also Published As

Publication number Publication date
JP2011521981A (ja) 2011-07-28
HK1152936A1 (en) 2012-03-16
US20160024033A1 (en) 2016-01-28
US20140206760A1 (en) 2014-07-24
CR11807A (es) 2011-02-16
US9688645B2 (en) 2017-06-27
TW201008917A (en) 2010-03-01
MX2010012793A (es) 2010-12-14
US20140039011A1 (en) 2014-02-06
CN102056922B (zh) 2013-11-20
EP2300462B1 (de) 2014-05-21
KR20110020795A (ko) 2011-03-03
AR072007A1 (es) 2010-07-28
WO2009146802A1 (de) 2009-12-10
PL2300462T3 (pl) 2014-10-31
BRPI0913349A2 (pt) 2015-11-24
CY1115604T1 (el) 2017-01-04
CN102056922A (zh) 2011-05-11
ES2494390T3 (es) 2014-09-15
KR101673886B1 (ko) 2016-11-08
AU2009254257B2 (en) 2013-11-21
US20160251324A1 (en) 2016-09-01
AU2009254257A1 (en) 2009-12-10
IL209772A (en) 2016-04-21
PT2300462E (pt) 2014-08-05
SI2300462T1 (sl) 2014-09-30
ZA201007719B (en) 2011-07-27
RU2010154089A (ru) 2012-07-20
DOP2010000363A (es) 2010-12-15
US8580777B2 (en) 2013-11-12
CA2726554C (en) 2015-02-24
US8722655B2 (en) 2014-05-13
CA2726554A1 (en) 2009-12-10
CL2009001358A1 (es) 2009-11-27
ECSP10010655A (es) 2011-01-31
CO6321271A2 (es) 2011-09-20
TWI455928B (zh) 2014-10-11
IL209772A0 (en) 2011-02-28
RU2502736C2 (ru) 2013-12-27
US9126955B2 (en) 2015-09-08
US9309207B2 (en) 2016-04-12
SV2010003747A (es) 2011-03-15
NI201000203A (es) 2011-09-29
DK2300462T3 (da) 2014-08-18
NZ589671A (en) 2012-03-30
US20110178130A1 (en) 2011-07-21
UA104002C2 (ru) 2013-12-25
HN2010002558A (es) 2012-08-28
UY31868A (es) 2010-01-05
EP2300462A1 (de) 2011-03-30
MA32322B1 (fr) 2011-05-02
JP5531011B2 (ja) 2014-06-25

Similar Documents

Publication Publication Date Title
ES2941512T3 (es) Compuestos de imidazo-piridina como inhibidores de PAD
ES2983048T3 (es) Compuestos heterocíclicos como inhibidores de PAD
RU2010154089A (ru) Макроциклические производные мочевины и сульфамида в качестве ингибиторов tafia
CN106518924B (zh) 用于治疗nk-1受体相关疾病的取代的4-苯基吡啶
ES2471970T3 (es) Derivados de tieno-piridina como inhibidores de MEK
ES2938648T3 (es) Inhibidores selectivos de JAK1
ES2617905T3 (es) Inhibidores de desmetilasas de histonas
JP5183647B2 (ja) ４−ピリジルアルキルチオ基を置換基として有する新規化合物
CN117586280A (zh) Kras g12d抑制剂及其在医药上的应用
ES2384121T3 (es) Compuestos de N-hidroxiacrilamida
JP2010514715A5 (enExample)
EP2038283A2 (en) Heterobicyclic metalloprotease inhibitors
JP2011521981A5 (enExample)
CN101321753A (zh) 用于治疗痴呆和神经变性疾病的糖原合酶激酶3抑制剂的新咪唑并[4,5-b]吡啶衍生物
JP2010514718A5 (enExample)
EA003697B1 (ru) Дизамещенные бициклические гетероциклы, их получение и применение в качестве лекарственных средств
ES2671502T3 (es) Proceso novedoso para preparar compuestos para su uso en el tratamiento de cáncer
RU2375356C2 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ TAFIa
ES2933504T3 (es) Sal farmacéuticamente aceptable de alquilcarbamoil naftaleniloxi octenoil hidroxiamida o de sus derivados y método para preparar la misma
RU2446157C2 (ru) Изосериновые производные для применения в качестве ингибиторов фактора свертывания крови ixa
CN105085478B (zh) 异喹啉磺胺衍生物及其药物组合物和制药用途
AU2015291477A1 (en) Novel 2,5-substituted pyrimidines as PDE inhibitors
HUE034254T2 (en) Substituted condensed pyrimidine compounds
HRP20150514T1 (hr) DERIVATI SULFAMIDA KAO INHIBITORI TAFIa
RU2010136941A (ru) Соли триазолия в качестве ингибиторов par1, их получение и применение в качестве лекарственного средства